Dr. Toni Choueiri on Nivolumab and Cabozantinib Becoming First-Line Therapies in RCC

Video

Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC.

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the potentials of both nivolumab and cabozantinib becoming first-line therapies for patients with renal cell carcinoma (RCC).

Choueiri says that while both drugs have a chance to become first-line therapies, nivolumab does more so than cabozantinib. He says there is a phase III study that has recently finish accrual that looks at combining nivolumab and ipilimumab, in comparison to sunitinib, as a treatment for RCC. The study's primary endpoints are progression-free survival and overall survival, and the study focuses on patients with intermediate to poor risk diagnoses.

Recent Videos
Related Content